A Phase II Study of BKM120; a Pan-PI3K Inhibitor in Patients With Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy
Latest Information Update: 13 Oct 2021
At a glance
- Drugs Buparlisib (Primary)
- Indications Carcinoma; Oesophageal cancer
- Focus Therapeutic Use
- 03 Oct 2021 Status changed from recruiting to discontinued.
- 19 Oct 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2016 as reported by ClinicalTrials.gov.
- 13 Mar 2013 New trial record